Eyenovia Inc. has reported its financial results for the first quarter of 2025, highlighting a net loss of $3.5 million. This marks an improvement compared to the net loss of $10.9 million recorded for the first quarter of 2024. The company's research and development expenses have significantly decreased to $0.7 million, down from $4.4 million in the same period of the previous year, representing an 85% reduction. General and administrative expenses also declined by 35% to $2.4 million from $3.6 million. Overall, total operating expenses for the first quarter of 2025 were reduced by 70%, amounting to $3.0 million compared to $10.1 million in the first quarter of 2024. In terms of liquidity, Eyenovia's unrestricted cash and cash equivalents as of March 31, 2025, stood at $3.9 million, an increase from $2.1 million as of December 31, 2024. The company has also made progress in reducing its ongoing cash burn by approximately 70% compared to the prior year and has improved debt repayment terms. Additionally, Eyenovia continues to negotiate a potential merger with Betaliq, a clinical-stage private pharmaceutical company, extending the exclusivity period to June 7, 2025, to finalize the merger agreement. The company is also advancing the development of its Optejet user-filled device, with plans to file for U.S. regulatory approval in September 2025.